The MarketWatch News Department was not involved in the creation of this content. BETHESDA, Md., April 17, 2026 /PRNewswire/ -- Precision Biologics, Inc. announces a new target in Acute Myeloid ...
Blood Cancer United announced today that new data across its portfolio of funded research will be presented in more than 50 ...
Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML). This is an ASCO ...
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Prospective assessment of ...
Please provide your email address to receive an email when new articles are posted on . Down syndrome remained a significant risk factor for pediatric leukemia, especially acute myeloid leukemia, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amphivena Therapeutics highlighted initial data from the dose-escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with ...
BETHESDA, Md., April 17, 2026 /PRNewswire/ -- Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results